About the ALS Therapy Development Institute (ALS TDI)

The ALS Therapy Development Institute (ALS TDI) is the largest drug discovery institute in the world focused solely on finding the many drugs that are needed to effectively treat everyone with ALS.

Their cutting-edge approach to ALS research incorporates every aspect of drug discovery and development, under one roof, to find potential treatments as quickly as possible. 

As a nonprofit biotech, ALS TDI operates without regard to profit or politics, and they are supported by a global community united in ending ALS. They spend 87 cents of every dollar raised on finding effective treatments and cures for ALS. 

ALS TDI’S IMPACT

ALS TDI’s cutting-edge approach has resulted in:

• ALS TDI becoming the first nonprofit biotech in any disease to invent a potential treatment, tegoprubart, and bring it from our own lab, through FDA review, and into a clinical trial.

• The world’s first ALS Precision Medicine Program (PMP), a comprehensive natural history study that partners with people with ALS to learn more about the disease and find potential treatments faster.

• The rigorous testing of over 500 drugs in animal models of ALS—more than any other ALS research lab in the world.

ALS TDI will not stop until everyone with ALS has effective treatments.

ALS TDI’s research is funded by a global network of supporters whose lives have been affected by this disease and who are unified to end ALS. Learn more at www.als.net.

“Beginning in 2021, our objective is to advance a new therapy into human clinical testing every two years – until everyone with ALS has effective treatments.” - Fernando Vieira M.D., CEO and Chief Scientific Officer